Open Interest and Volume Dynamics
On 24 June 2026, Sun Pharma's open interest (OI) in derivatives rose sharply to 1,26,316 contracts, up 10.49% from the previous day's 1,14,320 contracts. This increase of 11,996 contracts indicates a fresh influx of positions, reflecting heightened trader interest. Concurrently, the volume stood at 59,701 contracts, underscoring active participation in the futures and options market.
The futures segment alone accounted for a substantial value of ₹1,43,975.54 lakhs, while the options segment's notional value was significantly higher at ₹24,769.86 crores. The combined derivatives turnover reached ₹1,45,273.77 lakhs, highlighting robust liquidity and investor engagement.
Price Action and Technical Positioning
Sun Pharma's underlying share price closed at ₹1,875, just 2.22% shy of its 52-week high of ₹1,916.60. The stock has been on a consistent upward trajectory, gaining 4.13% over the last six trading sessions. This steady rally is supported by the stock trading above all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – signalling strong technical momentum.
The narrow trading range of ₹17.2 on the day suggests consolidation near resistance levels, often a precursor to a breakout. Rising delivery volumes, which increased by 20.66% to 14.92 lakh shares on 23 June, further confirm growing investor conviction and participation in the stock.
Market Positioning and Potential Directional Bets
The surge in open interest coupled with rising volumes typically indicates fresh directional bets rather than mere position rollovers. Given the stock's proximity to its 52-week high and positive price momentum, market participants appear to be positioning for further upside. The increase in futures open interest suggests that traders are taking long positions, anticipating continued gains in the near term.
Options market activity, with a substantial notional value, points to active hedging and speculative strategies. The elevated options value relative to futures indicates that investors may be employing complex strategies such as spreads or protective puts to manage risk while maintaining bullish exposure.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Comparative Performance and Sector Context
Sun Pharma's 1-day return of 0.54% outpaced the Pharmaceuticals & Biotechnology sector's gain of 0.18%, though it lagged slightly behind the broader Sensex's 0.98% rise. This relative outperformance within its sector highlights the stock's growing appeal among investors amid a mixed market backdrop.
With a market capitalisation of ₹4,50,619.10 crore, Sun Pharma remains a dominant large-cap player in the Pharmaceuticals & Biotechnology industry. Its Mojo Score of 74.0 and recent upgrade from Hold to Buy on 8 June 2026 reflect improving fundamentals and positive analyst sentiment.
Liquidity and Trading Viability
The stock's liquidity remains robust, with the average traded value supporting trade sizes up to ₹8.55 crore based on 2% of the 5-day average traded value. This level of liquidity ensures that institutional and retail investors can execute sizeable trades without significant market impact, an important consideration for derivatives traders.
Such liquidity, combined with rising open interest and volume, creates an environment conducive to active trading and potential volatility, which can be advantageous for derivative strategies.
Thinking about Sun Pharmaceutical Industries Ltd? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this large-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
Outlook and Investor Considerations
Given the current market positioning, investors should monitor the sustainability of the open interest increase and volume trends. A continued rise in OI alongside price appreciation would confirm a strong bullish bias, while any divergence could signal profit-taking or a potential reversal.
Sun Pharma's recent upgrade to a Buy rating by MarketsMOJO, supported by a Mojo Grade of 74.0, suggests favourable medium-term prospects. However, investors should remain cautious of broader market volatility and sector-specific risks such as regulatory changes or pricing pressures.
Overall, the derivatives market activity points to growing confidence in Sun Pharma's near-term upside potential, making it a stock to watch closely for both traders and long-term investors.
Summary
Sun Pharmaceutical Industries Ltd is currently exhibiting strong signs of bullish momentum, evidenced by a 10.49% surge in open interest and rising volumes in its derivatives segment. The stock’s proximity to its 52-week high, coupled with consistent gains and robust liquidity, underlines positive market sentiment. With an upgraded Buy rating and solid technical positioning, Sun Pharma remains a compelling large-cap stock within the Pharmaceuticals & Biotechnology sector.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
